LL-37 (cathelicidin): what it is, how people use it, and what the evidence shows

LL-37 is unusual among the peptides sold online, because it is no lab invention: it is a molecule your own body makes and uses as part of its first line of defense against infection. That real biology is exactly why the marketing around it is so easy to inflate. Vendors describe it as an all-purpose antimicrobial and immune “reset,” and the caveats about evidence and safety tend to fall away. This page puts them back, with a primary source for every claim, including why the same peptide can calm inflammation in one setting and drive it in another. It is educational only, and nothing here is medical advice. For the wider landscape of approved drugs and unapproved compounds, start with our explainer on what peptides are.

What is LL-37?

LL-37 is the only cathelicidin found in humans, a 37-amino-acid peptide that acts as a host-defense molecule in the body’s innate immune system. It does not circulate as a finished peptide on its own; it is cut from a larger precursor. A 2025 review in Inflammation Research describes how the pro-form of LL-37, hCAP18, is secreted by white blood cells and epithelial cells and processed to LL-37 extracellularly by serine proteases. The name is literal: the mature peptide is 37 residues long and begins with two leucine amino acids, hence “LL-37.” It is encoded by a single gene called CAMP (cathelicidin antimicrobial peptide), and the precursor is stored in the granules of neutrophils.

That last point is the one worth holding onto, because it separates LL-37 from most compounds in the research-peptide market. A 2012 study of healthy adults notes that the CAMP gene product is packaged in secondary granules of neutrophils and expressed by a wide array of immune cells and tissues that are constantly exposed to microbes including the skin, mouth, airways, intestine and colon. The same work reports that the CAMP gene is regulated at the level of transcription by the bioactive form of vitamin D, and that circulating levels of the peptide track with a person’s vitamin D status. So LL-37 is a genuine, endogenous part of human immunity, not a novel molecule someone designed. That pedigree is real and interesting, but by itself it is not evidence that injecting extra LL-37 from a vial is safe or useful, which the rest of this page takes up one question at a time. For the record, LL-37 is not a steroid, not a hormone, and not a controlled substance; the word “peptide” describes its chemistry, not its safety or its approval status.

How is LL-37 thought to work?

LL-37 is thought to work in two broad ways, by physically damaging microbes and by signaling to the immune system, but almost everything known about the detail comes from cell and animal experiments rather than human ones. On the antimicrobial side, LL-37 is a positively charged, amphipathic peptide that is drawn to the negatively charged surfaces of bacteria. The 2025 review states plainly that the peptide shows toxicity towards both gram-negative and gram-positive bacteria, and it acts via permeabilization of the bacterial cell wall, because LL-37 is a cationic peptide binding to negative moieties of plasma membranes. In plain terms, it punches holes in the outer envelopes of bacteria, unlike a conventional antibiotic.

The second role, immune signaling, is more nuanced. The same review describes how the peptide binds and inactivates lipopolysaccharide (LPS) and lipoteichoic acid (LTA), the inflammatory components of bacterial walls, effectively mopping up the debris that would otherwise trigger an over-reaction. It also reports that LL-37 triggers chemokine production by airway and colonic epithelial cells, helping recruit immune cells, and that it promotes wound healing and epithelial cell proliferation through a growth-factor receptor pathway. The honest framing is that these are proposed, biologically plausible actions observed mostly in cultured cells and rodents, not confirmed pathways of clinical benefit in a living person. The review’s own authors are explicit that it is important to examine the multiple actions of LL-37 in complex experimental set-ups, such as co-culture systems with many cell types, and of course in vivo, which is a plain acknowledgment that the human-relevant work is still to be done.

What is LL-37 studied and marketed for?

LL-37 is studied and marketed mainly for four overlapping goals: fighting infection, modulating the immune system, reducing inflammation, and supporting wound repair. It is important to read those as areas of active laboratory investigation, not as proven uses, because the wording of an ad (“a natural antibiotic that resets your immune system”) and the wording of the science (“permeabilized a bacterial membrane in a dish”) are not the same claim. In the research literature, the interest clusters around LL-37’s antimicrobial activity against drug-resistant bacteria, its ability to disrupt bacterial biofilms, its neutralizing effect on bacterial endotoxin, and its involvement in tissue repair. Vendors widen that same story into open-ended promises about immunity, gut health, skin, and recovery.

The network’s deeper, evidence-first pages examine the immune and inflammatory claims in detail rather than asserting them here:

• Immune modulation: our sister publication’s deep dive on how immune-focused peptides are actually studied lays out why “boosting” immunity is the wrong mental model and what the immunology really shows.
• Inflammation and the gut: for the peptide most often discussed alongside LL-37 for inflammatory goals, see what the KPV and inflammation research actually shows, study by study.
• Sibling overviews in this directory: our KPV overview covers the anti-inflammatory tripeptide most discussed for gut and immune research, and our thymosin alpha-1 overview covers the immune-modulating peptide that is a licensed medicine abroad but not in the United States.

Treat every one of those marketed uses as being investigated, not established; the evidence section below describes what has actually been demonstrated, and in which system.

What does the evidence actually show?

Almost all of the supporting evidence for LL-37 comes from cells and animals, not from humans, and the most important finding is that its effects are genuinely two-sided. A review titled “Significance of LL-37 on Immunomodulation and Disease Outcome” states the core tension directly: on the one side, LL-37 promotes inflammation and immune response and exerts its anti-infective and antitumor effects; on the other side, it has the ability to inhibit inflammation and promote carcinogenesis. Its authors put it more bluntly still: the immunomodulatory function of LL-37 has its two sides, and LL-37 can help the body maintain homeostasis, but once this steady state is broken, LL-37 can become a disease-causing factor. A marketing pitch treats “modulates the immune system” as unambiguously good; the science treats it as context-dependent and, in the wrong setting, harmful.

The disease associations researchers study most are mostly observational, not trials of LL-37 as a treatment. In psoriasis, LL-37 is overexpressed in inflamed skin and does something striking: a review of its role in autoimmune disease describes how LL-37 was found to be able to convert non-stimulatory self-DNA into a potent trigger of immune cells that then pour out interferon, and that LL-37 complexed to self-DNA acts as autoantigen in psoriasis. The same mechanism appears in lupus, where the review notes that LL-37/self-DNA complexes are abundantly released by neutrophils in the form of NETs in SLE and can become targets of the immune attack. In cancer the direction of effect flips by tumor type: a 2015 review reports that in breast, lung, and prostate cancers, LL-37 promotes proliferation, migration, and tumorigenesis, but in other types of cancers, such as gastric cancer, colon cancer, and T-cell leukemia, it can suppress proliferation and induce apoptotic and autophagic cell death, and that there is no conclusive evidence to explain the opposite effects in various cancers.

The honest summary is precise. There is a substantial body of laboratory work showing LL-37 is a biologically active molecule with antimicrobial and immune-signaling functions. What does not exist is a completed, published human trial demonstrating that giving supplemental LL-37 safely improves any of the outcomes it is marketed for. The 2025 mechanistic review is candid that even the peptide’s cell-killing activity is not clearly a benefit, writing that there is no direct evidence that LL-37-induced cytotoxicity is beneficial. Preclinical activity and human proof are different things, and LL-37 sits almost entirely on the preclinical side of that line. Anyone presenting its dish-and-rodent findings as human efficacy is skipping the step that matters, and dropping the half of the evidence that shows the molecule can cut the wrong way.

What are the reported side effects and safety unknowns?

LL-37’s human safety profile as an injected or supplemental compound is essentially unknown, and the laboratory record gives a specific reason for caution: the same membrane-disrupting property that kills bacteria also damages human cells at high enough concentrations. A study of LL-37 and its analogs reports that LL-37 causes hemolysis and is toxic to human leukocytes and the T-lymphocyte MOLT cell line, probably due to hydrophobic interactions with the eukaryotic cell membrane, and that it can induce apoptosis in vascular smooth muscle cells. This host toxicity is concentration-dependent, which is why researchers developing LL-37-based drugs treat it as a central obstacle. A 2024 paper working on LL-37-derived antimicrobials names the problem outright: one significant concern is the cytotoxicity observed at higher peptide concentrations, which indicates a potential risk of adverse effects in clinical settings where high doses might be required, and it frames the whole engineering effort as an attempt to improve the therapeutic index to make them safe for human use. The plain reading is that even scientists who want to turn LL-37 into a medicine consider unmodified LL-37’s toxicity a real barrier to human use.

A second, subtler concern follows directly from the evidence above: the molecule’s own biology can turn against the host. The autoimmune findings in psoriasis and lupus mean LL-37 is not a uniformly “protective” peptide; in the wrong context it is part of the machinery that drives chronic inflammatory disease. No one has established a safe dose, duration, or long-term effect of supplemental LL-37 in a person, and adding more of a molecule that can feed inflammation is not obviously benign.

Layered on top of both biological problems is a product-quality problem specific to how LL-37 is sold. Because it is not a regulated medicine, it is distributed by online vendors as a “research use only” chemical, a label meaning the product is not offered for human use and is not required to be sterile, correctly identified, or accurately dosed. A vial carries no guarantee that it contains what the label claims, at the purity and sterility an injection would demand, and a non-sterile injected product adds its own infection risk. So the safety picture stacks three uncertainties at once: what the molecule does to human cells at the doses people use, whether its immune effects help or harm in a given body, and whether the vial even contains real, clean LL-37.

Is LL-37 banned in sport?

In practice, yes. LL-37 is not individually named on the World Anti-Doping Agency’s Prohibited List, but that list’s S0 category for unapproved substances is a catch-all: as the US Anti-Doping Agency explains for the comparable experimental peptide BPC-157, a compound with no current regulatory approval for human use is prohibited under S0. LL-37 is in that same position, so an athlete in a tested sport should treat it as prohibited at all times.

What are people saying about LL-37?

LL-37 gets name-checked far more than it gets discussed. In 13 posts on X that our community tracker collected between July 10 and 14, 2026, most mentions were in peptide cheat sheets, catalogs and general guides rather than first-hand accounts. The threads that did go deeper covered three things:

• What it is. Posters describe it, accurately, as an antimicrobial peptide the immune system makes on demand that disrupts bacterial membranes, and one added that it supports tissue repair and blood-vessel growth.
• Hard infections. One commenter called LL-37 underrated and claimed it helps with MRSA. That is a hope, not a documented result in these threads, and nobody described personal use for it.
• Vitamin D. Several posts connect vitamin D to the body’s own production of cathelicidin and other antimicrobial peptides, as a broader immune-health point rather than a reason to inject LL-37.

The pattern matters: lots of list posts and enthusiasm, very few personal reports, and none of the caution about the molecule’s pro-inflammatory side that the evidence section above describes.

How to think about LL-37

If you are weighing LL-37, the most useful first move is to separate the chemistry from the claims. The chemistry is real, an endogenous human host-defense peptide with well-documented antimicrobial and immune-signaling activity in the laboratory. The claims are mostly hope built on cell and animal data, and they omit that the same molecule can promote inflammation, feed autoimmune disease, damage human cells at higher concentrations, and even help some tumors grow.

If your actual goal is a stubborn infection, an immune concern, or a skin or inflammatory condition, start with that goal, ideally with a licensed clinician, who may well suggest something other than the compound you came in asking about. To arrive at that conversation prepared, our sister publication’s guide to the questions to ask a provider about peptides is a good place to start.

Status: Not FDA-approved. What this status means.

Educational information only, not medical advice. Every scientific statement on this page is sourced to the primary references linked above. Updated October 12, 2026.